Description
Exelixis’ Hidden Growth Engine: A $1.5 Billion Colorectal Cancer Opportunity Awaits!
Exelixis, Inc. reported its third quarter of 2026 financial and operational results, highlighting continued growth in its core cabozantinib (CABO) franchise alongside advancing development of its second major pipeline candidate, zanzalintinib (zanza). Total revenues for the quarter reached approximately $659 million, driven primarily by $605 million in U.S. net product revenues from the cabozantinib franchise, representing an 11% year-over-year increase. Globally, cabozantinib revenue, including sales from partner companies Ipsen and Takeda, grew 11% to $818 million. The cabozantinib franchise maintains leadership positions as the number one tyrosine kinase inhibitor (TKI) plus immuno-oncology (IO) combination in renal cell carcinoma (RCC) and the leading oral therapy in the second-line-plus neuroendocrine tumor (NET) segment. Prescription volume and market share gains in the RCC and NET indications contribute positively to the company’s current revenue base.



